Nexalin Technology, Inc.正式披露将开展具有里程碑意义的Halo™ Clarity临床试验。该试验旨在为计划中的De Novo美国食品药品监督管理局（FDA）申请提供关键数据支持，目标直指全球规模达数百亿美元的失眠治疗市场。
Nexalin Technology, Inc.正式披露将开展具有里程碑意义的Halo™ Clarity临床试验。该试验旨在为计划中的De Novo美国食品药品监督管理局（FDA）申请提供关键数据支持，目标直指全球规模达数百亿美元的失眠治疗市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.